Viralkumar Amrutiya, MD
Nephrology · Melbourne, FLNPI 1356832935
Payments from drug & device makers
Across 36 payments — averaging $43.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$224
- Novo Nordisk$214
- Mallinckrodt Hospital Products Inc.$186
- Vantive US Healthcare LLC$152
- Calliditas Therapeutics US Inc.$143
- AstraZeneca$123
- plus $510 from 8 others
What the payments were for
- Food & beverage$1,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $224 |
| Novo Nordisk | 4 | $214 |
| Mallinckrodt Hospital Products Inc. | 8 | $186 |
| Vantive US Healthcare LLC | 3 | $152 |
| Calliditas Therapeutics US Inc. | 5 | $143 |
| AstraZeneca(2 entities) | 3 | $123 |
| Nxstage Medical, Inc. | 1 | $118 |
| Akebia Therapeutics Inc | 1 | $85 |
| Bayer | 1 | $74 |
| Novartis | 1 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Veloxis Pharmaceuticals, Inc. | 2 | $45 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$224
- Ozempic$125
- NXSTAGE SYSTEM ONE$118
- PUREFLOW SL$118
- Renal - PD$112
How this compares
$1,553 in reported general payments places this provider in the 45th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Melbourne
- Claus SpiesMelbourne$854K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.